Thursday, July 24, 2014

XTL hopes to begin major lupus trial next year

XTL hopes to begin major lupus trial next year

July 22, 2014 by · Leave a Comment 

Tweet XTL Biopharmaceuticals (NASDAQ:XTLB; TASE:XTL) is aiming to begin a Phase 2b clinical trial in the first half of 2015 with its hCDR1 peptide to treat patients with systemic lupus erythematosus (SLE). “We are in the process of finalizing our trial design, approaching the FDA and hope to have feedback from the agency before the […]

Cynapsus to start Phase 2 trial of APL-130277


Cynapsus to start Phase 2 trial of APL-130277


July 17, 2014 by · Leave a Comment 

Tweet Following communication from the FDA, Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) announced that it will begin Phase 2 clinical studies for APL-130277 immediately. The CTH-105 study will be initiated according to a proposal submitted to the FDA under the company’s IND application. APL-130277 is an easy-to-administer, fast-acting reformulation of apomorphine, which is the only approved drug […]

Venaxis responding to FDA questions on APPY1 Test

Venaxis responding to FDA questions on APPY1 Test

July 16, 2014 by · Leave a Comment 

Tweet The FDA has reviewed Venaxis’ (NASDAQ:APPY) submission to market its APPY1 Test and has provided the company with questions and information requests about the submission. The CE Marked APPY1Test is a multi-analyte assay for aiding in identifying children, adolescent and young adult patients that are at low risk for appendicitis. Venaxis is compiling responses […]

Cantor starts Radius Health at buy

Cantor starts Radius Health at buy

July 16, 2014 by · Leave a Comment 

Tweet Cantor Fitzgerald has initiated coverage of Radius Health (NASDAQ:RDUS) with a “buy” rating and $20 price target. The stock closed at $13.05 on Wednesday. “We like the simplicity of the company’s value proposition: a late-stage asset with near-term revenue potential, with the potential to cannibalize a $1-billion product in a market with strong demographic […]

Stifel starts Kite Pharma at buy

Stifel starts Kite Pharma at buy

July 15, 2014 by · Leave a Comment 

Tweet Stifel Nicholas has launched coverage of Kite Pharma (NASDAQ:KITE) with a “buy” rating and $31 target price. The stock closed at $24.05 on Monday “We believe that Kite’s lead drug KTE-C19 has the potential to surpass $1-billion in worldwide sales, treating diffuse large B-cell lymphoma (DLBCL),” writes analyst Joel Sendek. He views the 80% […]

HCW starts IntelGenx at buy

HCW starts IntelGenx at buy

June 30, 2014 by · Leave a Comment 

Tweet H.C. Wainwright has initiated coverage of IntelGenx (OTCQX:IGXT; TSX-V:IGX) with a “buy” rating and price target of $2. The stock closed at 70 cents on Friday. “The shares of IntelGenx seem to be high risk as management needs to resolve issues with their current marketed product and two products that are under FDA review,” […]

Verisante in sales pact for Core device in China

Verisante in sales pact for Core device in China

June 25, 2014 by · Leave a Comment 

Tweet Verisante Technology (OTCQX:VRSEF; TSX-V:VRS) has closed a $300,000 private placement in conjunction with signing a letter of intent with a strategic partner for the exclusive marketing and sales rights in China for its Core device for the detection of lung, colon, cervical and nasal cancer, and for the complementary ClearVu endoscopic camera. Under the […]

Canaccord upgrades AngioDynamics to buy

Canaccord upgrades AngioDynamics to buy

June 19, 2014 by · Leave a Comment 

Tweet Canaccord Genuity has upgraded AngioDynamics (NASDAQ:ANGO) to “buy” from “hold” and raised its 12-month price target to $20 from $16.25 after the company received FDA approval for the Celerity tip location system. The stock closed at $15.31 on Wednesday. “We believe improving business trends and strong cash generation will drive growth over the next […]

Roth ups EnteroMedics price target to $5

Roth ups EnteroMedics price target to $5

June 18, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has raised its price target for “buy-rated” EnteroMedics (NASDAQ:ETRM) to $5 from $3 after the FDA’s Gastroenterology-Urology Device Advisory Panel voted that the benefits of the company’s Maestro System outweigh the risks by a margin of six-to-two, with one abstention. Shares of EnteroMedics closed at $1.52 on Tuesday. On safety, the […]

Analysts start Agile Therapeutics at buy, outperform

Analysts start Agile Therapeutics at buy, outperform

June 17, 2014 by · Leave a Comment 

Tweet Janney Capital Markets, Cantor Fitzgerald and William Blair have launched coverage of Agile Therapeutics (NASDAQ:AGRX) at “buy” and “outperform” ratings. Janney analyst Kimberly Lee writes that the company’s combined hormonal contraceptive (CHC) patch, Twirla, “should improve patient compliance and provide efficacy and safety similar to low-dose oral contraceptives while targeting an unmet need for […]

Next Page »

Email Newsletters with Constant Contact
Google+